<Taiwania Capital is glad to announce Viracta, from San Diego, USA., to become our new partner of FundⅡ.>
Viracta Therapeutics Announces Closing of Series D Preferred Stock Financing
SAN DIEGO, Oct. 28, 2019 /PRNewswire/ — Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced the closing of a Series D Preferred Stock financing. The financing was led by Taiwania Capital Management, a Taiwan and US-based venture capital firm with $350 million in healthcare and technology funds, with participation from existing investors. In conjunction with the financing, Michael Huang, Managing Partner at Taiwania Capital Management, has been appointed to Viracta’s Board of Directors……………more details:►https://reurl.cc/GknMLD
